Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Disease
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 204540
Encorafenib is used to treat melanoma.
The Licensor is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
IPSCIO Record ID: 204233
Manufacturing License. Licensor hereby grants to Licensee a worldwide non-exclusive license under the Licensor Patents, Licensor Know-How and Licensor’s interests in the Joint Patents and Joint Know-How to (i) Manufacture and have Manufactured Binimetinib and Encorafenib for use in the Manufacture of Products, and (ii) Manufacture and have Manufactured Products, in each case for use in Developing and Commercializing such Products in accordance with the rights and license granted to Licensee. The licenses granted may be sublicensed by Licensee only to its Affiliates, and then only for so long as such entities remain as Affiliates. For clarity, the licenses granted may be extended by Licensee to Third Party manufacturers for Manufacturing the Products on Licensee’s behalf.
Commercialization License. Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses and appoint distributors as provided, under the Licensor Patents, Licensor Know-How Development License. Subject to the terms and conditions of this Agreement, including without limitation Licensor’s retained rights, Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses as provided, under the Licensor Patents, Licensor Know-How and Licensor’s interests in the Joint Patents and Joint Know-How to Develop the Products in accordance with the Development Plan and Joint Development Plan(s) in the Licensee Territory solely for purposes of obtaining Marketing Approval for use of the Product in the Field in the Licensee Territory.
Product means shall mean any pharmaceutical product containing, as an active ingredient, one or more of Binimetinib or Encorafenib, including, without limitation, any Combination Product.
Product Trademarks means (a) the product-specific trademarks owned or Controlled by Licensor and designated by Licensor for use with Products containing Binimetinib, (b) the product-specific trademarks owned or Controlled by Licensor and designated by Licensor for use with Products containing Encorafenib, and (c) any other product-specific trademark(s) and service mark(s) as may be proposed by either Party and reviewed by the JCC for use in connection with the distribution, marketing, promotion and sale of a Product in the Licensee Territory, or accompanying logos, trade dress or indicia of origin.
Licensor Know-How means, all scientific, medical, technical, manufacturing, marketing, regulatory, market access and other information (including clinical data and other related information generated in compliance with CDISC (Clinical Data Interchange Standards Consortium) standards) relating to Binimetinib, Encorafinib, a Product and/or any Companion Diagnostic useful with respect to the Development, Manufacturing, registration (including registration for MAA) or Commercialization of a Product (including the Data), to the extent Controlled by Licensor or its Controlled Affiliates as of the Effective Date or during the term of this Agreement, and needed by or reasonably useful to Licensee in order for Licensee to exercise its rights or perform its obligations under this Agreement. Licensor Know-How shall in any case include all such items that are generated by or under authority of Licensor, or any of its Affiliates, in connection with Development Manufacturing, and/or Commercialization of the Product during the term of this Agreement.
Binimetinib means the compound known as MEK162, the chemical structure as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph or radiolabeled equivalent thereof.
Encorafenib means the compound known as LGX818, the chemical structure as well as all salts, non-covalent complexes, hydrates, solvates, chelates, crystal polymorph, or radiolabeled equivalent thereof.
Joint Inventions means all inventions arising during the term of the Agreement that (a) are jointly created or reduced to practice by employees, consultants, or contractors of Licensor or its Affiliates and by employees, consultants, or contractors of Licensee or its Affiliates, and (b) relate to Binimetinib, Encorafenib and/or Products.
Joint Know-How means all know-how arising during the term of the Agreement that (a) is jointly generated by employees, consultants, or contractors of Licensor or its Affiliates and by employees, consultants, or contractors of Licensee or its Affiliates, and (b) relates to Binimetinib, Encorafenib and/or Products.
Joint Patent means a Patent that covers or claims a Joint Invention
Binimetinib is a MEK inhibitor being developed to treat various cancers.
Encorafenib, also known as LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase.
'These two compounds have shown promising efficacy and safety in the previous clinical trials and we believe that both compounds can be a new therapeutic option as a combination therapy for patients with BRAF-mutant melanoma, BRAF-mutant colorectal cancer and beyond.'
IPSCIO Record ID: 61018
(a) an exclusive royalty-bearing license, with the right to grant sublicenses solely as provided under the Company Technology to use, sell, offer for sale, import and otherwise Commercialize (but not to make or have made) the Products in the Field and in the Licensee Territory; and
(b) a non-exclusive license, with the right to grant sublicenses solely as provided under the Company Technology to Develop (but not to make or have made) the Products on a worldwide basis under the GDP, and to use the Products for that purpose. Exelixis agrees not to grant any further license to Develop the Products except to Future Exelixis Licensees.
Cobimetinib is a potent, highly selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors. It is indicated in combination with vemurafenib as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. The company is a biopharmaceutical company that discovers, develops and commercializes small molecule therapies for the treatment of cancer. The business focuses predominantly on the development and commercialization of cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is currently approved in the United States and European Union for the treatment of progressive, metastatic medullary thyroid cancer, or MTC, and is marketed under the brand name COMETRIQ®.
IPSCIO Record ID: 135967
